OPHTHALMIC DRUGS MARKET ANALYSIS
Global Ophthalmic Drugs Market: Key Developments
In May 2022, Alcon signed an agreement to acquire EYSUVIS (loteprednol etabonate suspension) pharmaceutical eye drops from Kala Pharmaceuticals, Inc. This acquisition will enhance Alcon’s current offering in the large and currently growing dry eye segment.
In April 2022, Sandoz launched generic combination eyedrop brimonidine tartrate/timolol maleate ophthalmic solution, an AB-rated generic equivalent to AbbVie’s COMBIGAN, to lower the eye pressure in patients with ocular hypertension (high eye pressure) in the United States.
In March 2022, Théa Pharma acquired seven branded ophthalmic products from Akorn Operating Company LLC to strengthen its position as a significant provider of products developed to satisfy the demands of eye care specialists across the United States.
In January 2022, Sun Pharma Canada Inc. launched Cequa (cyclosporine ophthalmic solution 0.09 percent w/v), a calcineurin inhibitor immunomodulator, to treat dry eye disease in Canada.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
